IDiyas

For the Inventor, By the Inventor

Virum, Denmark

Flemming E Nielsen

USPTO Granted Patents = 27

Average Co-Inventor Count = 3.4

ph-index = 10

Forward Citations = 268(Granted Patents)


Company Filing History:

goldMedal17 out of 1,777 
 
Novo Nordisk A/s
 patents
silverMedal5 out of 41 
 
A/s Ferrosan
 patents
bronzeMedal3 out of 50 
 
High Point Pharmaceuticals, LLC
 patents
4. 1 out of 1 
 
Novo Nordisk Ais
 patent
5. 1 out of 10 
 
Novo Nordiskals
 patents

Years Active: 1989-2011

Loading Chart...
27 patents (USPTO):Explore Patents
1. 8022066 - 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes (2011-09-20),
2. 7939690 - Haloalkylsulfone substituted compounds useful for treating obesity and diabetes (2011-05-10),
3. 7915299 - 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes (2011-03-29),
4. 6329367 - Fused 1,2,4-thiadiazine derivatives, their preparation and use (2001-12-11),
5. 6242443 - 1,2,4-benzothiadiazine derivatives, their preparation and use (2001-06-05),
6. 6225310 - Fused 1,2,4-thiadiazine derivatives, their preparation and use (2001-05-01),
7. 6001832 - [1,2,4]triazolo[4,3-a]quinoxalinone derivatives, their preparation and (1999-12-14),
8. 5889002 - Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their (1999-03-30),
9. 5792764 - Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, their (1998-08-11),
10. 5559106 - Heterocyclic compounds, their use and preparation (1996-09-24),
11. 5532236 - [1,2,4]triazolo[4,3-a]quinoxaline compounds (1996-07-02),
12. 5504085 - Triazolo quinoxalines and their preparation and use (1996-04-02),
13. 5308845 - Quinoxaline compounds and their preparation and use (1994-05-03),
14. 5182279 - Benzothienopyrazinedione compounds and their preparation and use (1993-01-26),
15. 5153195 - Quinoxaline compounds and their preparation and use (1992-10-06),

Title: Innovations of Flemming E. Nielsen: Patents and Career Overview

Introduction: Flemming E. Nielsen, based in Virum, Denmark, is a notable inventor with a significant contribution to the field of pharmacology, particularly in the treatment of obesity and diabetes. With a remarkable portfolio that includes 27 patents, he has been at the forefront of developing novel compounds aimed at tackling pressing health issues.

Latest Patents: Among his recent innovations are two notable patents. The first patent describes "2-(2-hydroxyphenyl) benzothiadiazines," which are chemical uncouplers useful in the treatment and prevention of obesity and diabetes, as well as a range of related diseases or conditions. The second patent involves "Haloalkylsulfone substituted compounds," also acting as chemical uncouplers. These compounds are designed with specific substituents that enhance their efficacy in combating obesity and diabetes.

Career Highlights: Flemming has worked with well-established companies, including Novo Nordisk A/S and A/S Ferrosan, where he has contributed to significant advancements in therapeutic solutions. His expertise in the synthesis of pharmaceutical compounds has led to the development of groundbreaking treatments that address critical health challenges worldwide.

Collaborations: Throughout his career, Flemming E. Nielsen has collaborated with distinguished colleagues, including Poul Jacobsen and Tage Honore. These partnerships have enriched his research and have played a crucial role in his success as an inventor.

Conclusion: Flemming E. Nielsen's contributions to the field of pharmacology are invaluable, as evidenced by his extensive patent portfolio and collaborative efforts within the industry. His innovative work continues to influence the development of treatments for obesity, diabetes, and associated conditions, showcasing the importance of fresh ideas in addressing global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…